|
G |
ATP7B |
ATPase copper transporting beta |
multiple interactions |
EXP |
Cyclic AMP inhibits the reaction [Copper binds to ATP7B protein] |
CTD |
PMID:21084060 |
|
NCBI chr11:15,892,549...15,942,070
Ensembl chr11:15,876,612...15,942,064
|
|
G |
CALCB |
calcitonin-related polypeptide beta |
increases abundance |
EXP |
CALCA protein results in increased abundance of Cyclic AMP |
CTD |
PMID:18463244 |
|
NCBI chr 2:44,043,135...44,048,651
|
|
G |
DUOX2 |
dual oxidase 2 |
increases expression |
EXP |
Cyclic AMP results in increased expression of DUOX2 mRNA |
CTD |
PMID:10601291 |
|
NCBI chr 1:126,620,468...126,641,406
Ensembl chr 1:126,620,510...126,641,406
|
|
G |
GCG |
glucagon |
affects response to substance increases abundance |
EXP |
Cyclic AMP affects the susceptibility to GCG protein GCG protein results in increased abundance of Cyclic AMP |
CTD |
PMID:6253273 |
|
NCBI chr15:68,800,557...68,810,268
Ensembl chr15:68,800,560...68,810,242
|
|
G |
GNRH1 |
gonadotropin releasing hormone 1 |
multiple interactions increases abundance |
EXP |
[Cobalt binds to GNRH1 protein] which results in increased abundance of Cyclic AMP GNRH1 protein results in increased abundance of Cyclic AMP |
CTD |
PMID:15833593 |
|
NCBI chr14:9,442,971...9,447,521
Ensembl chr14:9,442,971...9,453,035
|
|
|
G |
PDE5A |
phosphodiesterase 5A |
increases degradation |
EXP |
PDE5 protein results in increased degradation of Cyclic GMP |
CTD |
PMID:18669600 |
|
NCBI chr 8:104,270,858...104,420,955
Ensembl chr 8:104,270,881...104,420,953
|
|
G |
PDE6C |
phosphodiesterase 6C |
increases degradation |
EXP |
PDE6C protein results in increased degradation of Cyclic GMP |
CTD |
PMID:18669600 |
|
NCBI chr14:105,010,974...105,122,628
Ensembl chr14:105,050,691...105,122,421
|
|
G |
PRKG1 |
protein kinase cGMP-dependent 1 |
increases activity |
EXP |
Cyclic GMP results in increased activity of PRKG1 protein |
CTD |
PMID:18037907 |
|
NCBI chr14:97,558,531...98,793,080
Ensembl chr14:97,558,533...98,793,010
|
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
increases expression multiple interactions |
EXP |
Adenosine Triphosphate results in increased expression of BCL2 protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased expression of BCL2 protein] |
CTD |
PMID:17997382 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CASP8 |
caspase 8 |
increases activity multiple interactions |
EXP |
Adenosine Triphosphate results in increased activity of CASP8 protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased activity of CASP8 protein] |
CTD |
PMID:17997382 |
|
NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468
|
|
G |
CYCS |
cytochrome c, somatic |
affects localization multiple interactions |
EXP |
Adenosine Triphosphate affects the localization of CYCS protein [Calcium co-treated with Phosphates co-treated with Adenosine Triphosphate] affects the localization of CYCS protein; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate affects the localization of CYCS protein] |
CTD |
PMID:16489745 PMID:17997382 |
|
NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
|
|
G |
MYL9 |
myosin light chain 9 |
decreases phosphorylation multiple interactions |
EXP |
Adenosine Triphosphate results in decreased phosphorylation of MYL9 protein 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein]]; Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein] |
CTD |
PMID:10942722 |
|
NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,293
|
|
G |
TNF |
tumor necrosis factor |
increases expression multiple interactions |
EXP |
Adenosine Triphosphate results in increased expression of TNF protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased expression of TNF protein] |
CTD |
PMID:17997382 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
ATP1A1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression |
EXP |
Bucladesine results in increased expression of ATP1A1 protein |
CTD |
PMID:28438630 |
|
NCBI chr 4:104,353,506...104,384,321
Ensembl chr 4:104,353,508...104,384,547
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
Chlorpyrifos results in increased expression of BAX mRNA |
CTD |
PMID:34399389 PMID:38565334 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression |
EXP |
Chlorpyrifos results in decreased expression of BCL2 mRNA |
CTD |
PMID:34399389 PMID:38565334 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CASP3 |
caspase 3 |
increases expression increases cleavage |
EXP |
Chlorpyrifos results in increased expression of CASP3 mRNA Chlorpyrifos results in increased cleavage of CASP3 mRNA |
CTD |
PMID:34399389 PMID:38565334 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CAT |
catalase |
decreases expression |
EXP |
Chlorpyrifos results in decreased expression of CAT mRNA |
CTD |
PMID:34399389 PMID:38565334 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
DAAM1 |
dishevelled associated activator of morphogenesis 1 |
decreases expression |
EXP |
Chlorpyrifos results in decreased expression of DAAM1 mRNA; Chlorpyrifos results in decreased expression of DAAM1 protein |
CTD |
PMID:38565334 |
|
NCBI chr 1:188,335,335...188,511,094
Ensembl chr 1:188,335,384...188,511,096
|
|
G |
FSCN1 |
fascin actin-bundling protein 1 |
decreases expression |
EXP |
Chlorpyrifos results in decreased expression of FSCN1 mRNA; Chlorpyrifos results in decreased expression of FSCN1 protein |
CTD |
PMID:38565334 |
|
NCBI chr 3:4,134,173...4,143,275
Ensembl chr 3:4,134,177...4,143,286
|
|
G |
GJA1 |
gap junction protein alpha 1 |
increases expression |
EXP |
Chlorpyrifos results in increased expression of GJA1 mRNA; Chlorpyrifos results in increased expression of GJA1 protein |
CTD |
PMID:38565334 |
|
NCBI chr 1:40,988,818...41,002,129
Ensembl chr 1:40,988,528...41,002,156
|
|
G |
GPX2 |
glutathione peroxidase 2 |
decreases expression |
EXP |
Chlorpyrifos results in decreased expression of GPX2 mRNA |
CTD |
PMID:34399389 PMID:38565334 |
|
NCBI chr 7:89,007,636...89,011,620
Ensembl chr 7:89,007,375...89,011,620
|
|
G |
MYO10 |
myosin X |
decreases expression |
EXP |
Chlorpyrifos results in decreased expression of MYO10 mRNA; Chlorpyrifos results in decreased expression of MYO10 protein |
CTD |
PMID:38565334 |
|
NCBI chr16:5,907,111...6,145,485
Ensembl chr16:5,907,116...6,094,845
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
EXP |
Chlorpyrifos results in decreased expression of PTGS2 mRNA |
CTD |
PMID:38565334 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
SHAS2 |
hyaluronan synthase 2 |
decreases expression |
EXP |
Chlorpyrifos results in decreased expression of SHAS2 mRNA |
CTD |
PMID:38565334 |
|
NCBI chr 4:17,583,154...17,613,524
Ensembl chr 4:17,596,492...17,615,480
|
|
G |
SOD1 |
superoxide dismutase 1 |
decreases expression |
EXP |
Chlorpyrifos results in decreased expression of SOD1 mRNA |
CTD |
PMID:34399389 PMID:38565334 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
SOD2 |
superoxide dismutase 2 |
decreases expression |
EXP |
Chlorpyrifos results in decreased expression of SOD2 mRNA |
CTD |
PMID:34399389 PMID:38565334 |
|
NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560
|
|
G |
TNFAIP6 |
TNF alpha induced protein 6 |
decreases expression |
EXP |
Chlorpyrifos results in decreased expression of TNFAIP6 mRNA |
CTD |
PMID:38565334 |
|
NCBI chr15:862,013...881,352
Ensembl chr15:862,015...881,461
|
|
|
G |
APEH |
acylaminoacyl-peptide hydrolase |
decreases activity |
EXP |
chlorpyrifos-methyl results in decreased activity of APEH protein |
CTD |
PMID:10953051 |
|
NCBI chr13:32,205,863...32,214,517
Ensembl chr13:32,205,609...32,214,518
|
|
|
G |
ACHE |
acetylcholinesterase |
decreases activity |
EXP |
Diazinon results in decreased activity of ACHE protein |
CTD |
PMID:21467751 |
|
NCBI chr 3:8,732,451...8,738,274
Ensembl chr 3:8,732,441...8,738,605
|
|
|
G |
ACHE |
acetylcholinesterase |
decreases activity |
EXP |
Dichlorvos results in decreased activity of ACHE protein |
CTD |
PMID:21467751 |
|
NCBI chr 3:8,732,451...8,738,274
Ensembl chr 3:8,732,441...8,738,605
|
|
G |
APEH |
acylaminoacyl-peptide hydrolase |
decreases activity |
EXP |
Dichlorvos results in decreased activity of APEH protein |
CTD |
PMID:10953051 |
|
NCBI chr13:32,205,863...32,214,517
Ensembl chr13:32,205,609...32,214,518
|
|
G |
BCHE |
butyrylcholinesterase |
decreases activity |
EXP |
Dichlorvos results in decreased activity of BCHE protein |
CTD |
PMID:4631366 |
|
NCBI chr13:104,946,732...105,007,568
|
|
|
G |
APEH |
acylaminoacyl-peptide hydrolase |
decreases activity |
EXP |
Isoflurophate results in decreased activity of APEH protein |
CTD |
PMID:10953051 |
|
NCBI chr13:32,205,863...32,214,517
Ensembl chr13:32,205,609...32,214,518
|
|
G |
BCHE |
butyrylcholinesterase |
decreases activity |
EXP |
Isoflurophate results in decreased activity of BCHE protein |
CTD |
PMID:4631366 |
|
NCBI chr13:104,946,732...105,007,568
|
|
|
G |
ALPL |
alkaline phosphatase, biomineralization associated |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA |
CTD |
PMID:30481989 |
|
NCBI chr 6:79,589,695...79,649,646
Ensembl chr 6:79,589,045...79,649,644
|
|
G |
BCL2L1 |
BCL2 like 1 |
multiple interactions |
EXP |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:30481989 |
|
NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,143...35,414,694
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
[Troglitazone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CASP3 mRNA |
CTD |
PMID:30481989 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CEBPA |
CCAAT enhancer binding protein alpha |
multiple interactions |
EXP |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CEBPA mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CEBPA mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 6:43,083,200...43,085,884
Ensembl chr 6:43,083,207...43,085,836
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL1A1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL1A1 mRNA |
CTD |
PMID:30481989 |
|
NCBI chr12:26,379,087...26,397,180
Ensembl chr12:26,379,090...26,397,004
|
|
G |
CTNNB1 |
catenin beta 1 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr13:25,163,550...25,208,314
Ensembl chr13:25,164,277...25,208,311
|
|
G |
FABP4 |
fatty acid binding protein 4 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 4:55,096,400...55,101,209
Ensembl chr 4:55,096,404...55,101,896
|
|
G |
IGF1 |
insulin like growth factor 1 |
multiple interactions |
EXP |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,033
|
|
G |
IGF1R |
insulin like growth factor 1 receptor |
multiple interactions |
EXP |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1R mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1R mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 1:137,383,623...137,691,038
Ensembl chr 1:137,387,825...137,691,058
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA |
CTD |
PMID:30481989 |
|
NCBI chr 7:40,106,581...40,353,304
Ensembl chr 7:40,106,532...40,460,687
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340
|
|
|
G |
AKT2 |
AKT serine/threonine kinase 2 |
increases expression |
EXP |
Malathion results in increased expression of AKT2 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 6:48,555,785...48,620,472
Ensembl chr 6:48,555,795...48,587,919
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
Malathion results in increased expression of BAX mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression multiple interactions |
EXP |
Malathion results in decreased expression of BCL2 mRNA Melatonin inhibits the reaction [Malathion results in decreased expression of BCL2 mRNA] |
CTD |
PMID:31535366 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CAT |
catalase |
decreases expression multiple interactions |
EXP |
Malathion results in decreased expression of CAT mRNA Melatonin inhibits the reaction [Malathion results in decreased expression of CAT mRNA] |
CTD |
PMID:31535366 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
decreases expression |
EXP |
Malathion results in decreased expression of CYP1A1 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
decreases expression |
EXP |
Malathion results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 3:102,195,743...102,205,687
Ensembl chr 3:102,195,741...102,205,683
|
|
G |
DUOX2 |
dual oxidase 2 |
decreases expression |
EXP |
Malathion results in decreased expression of DUOX2 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 1:126,620,468...126,641,406
Ensembl chr 1:126,620,510...126,641,406
|
|
G |
GPX4 |
glutathione peroxidase 4 |
increases expression |
EXP |
Malathion results in increased expression of GPX4 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931
|
|
G |
GPX6 |
glutathione peroxidase 6 |
increases expression |
EXP |
Malathion results in increased expression of GPX6 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 7:22,256,013...22,267,992
Ensembl chr 7:22,256,038...22,267,992
|
|
G |
LOC106504562 |
glutathione S-transferase alpha M14 |
decreases expression |
EXP |
Malathion results in decreased expression of GSTA1 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 7:46,553,813...46,567,596
|
|
G |
MT-CO1 |
mitochondrially encoded cytochrome c oxidase I |
affects expression |
EXP |
Malathion affects the expression of COX1 mRNA |
CTD |
PMID:17454254 |
|
NCBI chr MT:6,511...8,055
Ensembl chr MT:6,511...8,055
|
|
G |
MT-CO3 |
mitochondrially encoded cytochrome c oxidase III |
affects expression |
EXP |
Malathion affects the expression of COX3 mRNA |
CTD |
PMID:17454254 |
|
NCBI chr MT:9,800...10,583
Ensembl chr MT:9,800...10,583
|
|
G |
PLIN2 |
perilipin 2 |
multiple interactions decreases expression |
EXP |
Melatonin inhibits the reaction [Malathion results in decreased expression of PLIN2 mRNA]; Melatonin inhibits the reaction [Malathion results in decreased expression of PLIN2 protein] Malathion results in decreased expression of PLIN2 mRNA; Malathion results in decreased expression of PLIN2 protein |
CTD |
PMID:31535366 |
|
NCBI chr 1:203,683,867...203,709,277
Ensembl chr 1:203,683,862...203,709,273
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions decreases expression |
EXP |
Melatonin inhibits the reaction [Malathion results in decreased expression of PPARG mRNA]; Melatonin inhibits the reaction [Malathion results in decreased expression of PPARG protein] Malathion results in decreased expression of PPARG mRNA; Malathion results in decreased expression of PPARG protein |
CTD |
PMID:31535366 |
|
NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944
|
|
G |
SLC34A2 |
solute carrier family 34 member 2 |
increases expression |
EXP |
Malathion results in increased expression of SLC34A2 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 8:19,481,127...19,507,903
Ensembl chr 8:19,481,198...19,509,666
|
|
G |
SOD2 |
superoxide dismutase 2 |
increases expression |
EXP |
Malathion results in increased expression of SOD2 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560
|
|
G |
SORD |
sorbitol dehydrogenase |
increases expression |
EXP |
Malathion results in increased expression of SORD mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 1:126,659,198...126,701,084
Ensembl chr 1:126,655,156...126,701,138
|
|
G |
TP53 |
tumor protein p53 |
increases expression multiple interactions |
EXP |
Malathion results in increased expression of TP53 mRNA Melatonin inhibits the reaction [Malathion results in increased expression of TP53 mRNA] |
CTD |
PMID:31535366 |
|
NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818
|
|
|
G |
ALDH7A1 |
aldehyde dehydrogenase 7 family member A1 |
multiple interactions |
EXP |
NAD promotes the reaction [Hydrogen Peroxide results in decreased activity of ALDH7A1 protein] |
CTD |
PMID:21296058 |
|
NCBI chr 2:129,663,226...129,709,728
Ensembl chr 2:129,662,969...129,709,705
|
|
|
G |
ALDH7A1 |
aldehyde dehydrogenase 7 family member A1 |
multiple interactions |
EXP |
NAD promotes the reaction [Hydrogen Peroxide results in decreased activity of ALDH7A1 protein] |
CTD |
PMID:21296058 |
|
NCBI chr 2:129,663,226...129,709,728
Ensembl chr 2:129,662,969...129,709,705
|
|
|
G |
LOC110256483 |
carbonyl reductase [NADPH] 1-like |
multiple interactions affects binding |
EXP |
NADP inhibits the reaction [4-hydroxymercuribenzoate results in decreased activity of CBR1 protein] NADP binds to CBR1 protein |
CTD |
PMID:15145449 |
|
NCBI chr13:199,713,741...199,719,535
|
|
|
G |
LOC110256483 |
carbonyl reductase [NADPH] 1-like |
affects binding multiple interactions |
EXP |
NADP binds to CBR1 protein NADP inhibits the reaction [4-hydroxymercuribenzoate results in decreased activity of CBR1 protein] |
CTD |
PMID:15145449 |
|
NCBI chr13:199,713,741...199,719,535
|
|
|
G |
ACHE |
acetylcholinesterase |
decreases activity multiple interactions |
EXP |
Paraoxon results in decreased activity of ACHE protein asoxime chloride inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; N,N'-monomethylenebis(pyridiniumaldoxime) inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Obidoxime Chloride inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; pralidoxime inhibits the reaction [Paraoxon results in decreased activity of ACHE protein] |
CTD |
PMID:19428926 PMID:20156534 PMID:20971170 PMID:22230262 |
|
NCBI chr 3:8,732,451...8,738,274
Ensembl chr 3:8,732,441...8,738,605
|
|
G |
BCHE |
butyrylcholinesterase |
decreases activity |
EXP |
Paraoxon results in decreased activity of BCHE protein |
CTD |
PMID:4631366 |
|
NCBI chr13:104,946,732...105,007,568
|
|
|
G |
ABCB4 |
ATP binding cassette subfamily B member 4 |
increases export multiple interactions |
EXP |
ABCB4 protein results in increased export of Phosphatidylcholines Itraconazole inhibits the reaction [ABCB4 protein results in increased export of Phosphatidylcholines]; Verapamil inhibits the reaction [ABCB4 protein results in increased export of Phosphatidylcholines] |
CTD |
PMID:21056966 |
|
NCBI chr 9:93,171,371...93,262,124
|
|
G |
PDIA3 |
protein disulfide isomerase family A member 3 |
increases hydrolysis |
EXP |
PDIA3 protein results in increased hydrolysis of Phosphatidylcholines |
CTD |
PMID:16798117 |
|
NCBI chr 1:127,786,174...127,814,096
Ensembl chr 1:127,785,772...127,814,196
|
|
|
G |
ACHE |
acetylcholinesterase |
multiple interactions decreases activity |
EXP |
N,N'-monomethylenebis(pyridiniumaldoxime) inhibits the reaction [VX results in decreased activity of ACHE protein] |
CTD |
PMID:20888357 |
|
NCBI chr 3:8,732,451...8,738,274
Ensembl chr 3:8,732,441...8,738,605
|
|